Eirion Therapeutics, Inc.

Eirion Therapeutics' ET-02 Shows Promise in Phase 1 Trial for Androgenic Alopecia

5 months ago

• Eirion Therapeutics reports positive Phase 1 results for ET-02, a topical treatment for androgenic alopecia, demonstrating safety and tolerability. • The trial showed a six-fold increase in non-vellus hair count compared to placebo after four weeks of daily application of the 5% ET-02 solution. • ET-02's novel, non-hormonal mechanism of action targets hair follicle stem cells and is expected to avoid side effects associated with existing treatments like finasteride. • A Phase 2 clinical trial is planned for 2025 to further evaluate the safety and efficacy of ET-02 over a six-month treatment period.

Eirion Therapeutics' AI-09 Shows Promise in Phase 1-2 Trial for Wrinkle Treatment

8 months ago

• Eirion Therapeutics' AI-09, a ready-to-use liquid injectable neuromodulator, demonstrated safety and efficacy in a Phase 1-2 trial for glabellar wrinkles. • The study showed a dose-response pattern, with higher doses achieving clinically and statistically significant improvements and a median duration of 26 weeks. • A survey indicated that 97% of neuromodulator users would prefer a 6-month treatment duration, highlighting the potential market appeal of AI-09. • Eirion is advancing its pipeline of aesthetic products, including topical neuromodulators and small molecules for hair loss, based on these positive results.

Eirion Therapeutics Initiates Phase 1 Trial of ET-02 for Androgenic Alopecia

a year ago

• Eirion Therapeutics has begun a Phase 1 clinical trial to assess the safety of topical ET-02 for treating androgenic alopecia (age-related hair loss). • The double-blind, placebo-controlled study will evaluate the safety of once-daily ET-02 treatment over 28 days in approximately 24 participants. • ET-02 targets hair follicle stem cells, aiming to restore their normal activity and function, potentially offering a more effective treatment than existing options. • Pre-clinical studies showed ET-02's potential to restore hair growth and normalize hair follicle structure, suggesting it may also prevent androgenic alopecia.